These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32279103)

  • 1. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
    Wei X; Nian J; Zheng J; He Y; Zeng M
    Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
    Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
    Biochem Biophys Res Commun; 2019 Jun; 513(3):589-593. PubMed ID: 30979499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
    Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
    Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
    Wang L; Chen Y; Li H; Xu Q; Liu R
    Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer.
    Kang MA; Kim W; Jo HR; Shin YJ; Kim MH; Jeong JH
    Int J Oncol; 2018 Aug; 53(2):703-712. PubMed ID: 29901072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
    Santo L; Vallet S; Hideshima T; Cirstea D; Ikeda H; Pozzi S; Patel K; Okawa Y; Gorgun G; Perrone G; Calabrese E; Yule M; Squires M; Ladetto M; Boccadoro M; Richardson PG; Munshi NC; Anderson KC; Raje N
    Oncogene; 2010 Apr; 29(16):2325-36. PubMed ID: 20101221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma.
    Zhang J; Jiang Y; Yu Y; Li J
    Eur J Pharmacol; 2022 Jan; 915():174688. PubMed ID: 34883074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
    Squires MS; Cooke L; Lock V; Qi W; Lewis EJ; Thompson NT; Lyons JF; Mahadevan D
    Mol Cancer Ther; 2010 Apr; 9(4):920-8. PubMed ID: 20354122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
    Xu M; Tao Z; Wang S; Jiang Y; Qu M
    Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoprenylcysteine carboxylmethyltransferase is associated with nasopharyngeal carcinoma chemoresistance and Ras activation.
    Zhu Y; Hu Q; Li H
    Biochem Biophys Res Commun; 2019 Aug; 516(3):784-789. PubMed ID: 31253403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Casein kinase 1α-dependent inhibition of Wnt/β-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity.
    Li J; Jiang Y; Wang P; Ke S; Yang L; Shen Y
    Anticancer Drugs; 2019 Aug; 30(7):e0747. PubMed ID: 31305293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK inhibition by trametinib overcomes chemoresistance in preclinical nasopharyngeal carcinoma models.
    Gong X; Fan L; Wang P
    Anticancer Drugs; 2021 Oct; 32(9):978-985. PubMed ID: 34282746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
    Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
    Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
    Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress.
    Li Q; Ni W; Deng Z; Liu M; She L; Xie Q
    Fundam Clin Pharmacol; 2017 Jun; 31(3):301-310. PubMed ID: 28078787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrin α5 mediates intrinsic cisplatin resistance in three-dimensional nasopharyngeal carcinoma spheroids via the inhibition of phosphorylated ERK /caspase-3 induced apoptosis.
    Ngaokrajang U; Janvilisri T; Sae-Ueng U; Prungsak A; Kiatwuthinon P
    Exp Cell Res; 2021 Sep; 406(2):112765. PubMed ID: 34358523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
    Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
    Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
    [No Abstract]   [Full Text] [Related]  

  • 19. ARNTL hypermethylation promotes tumorigenesis and inhibits cisplatin sensitivity by activating CDK5 transcription in nasopharyngeal carcinoma.
    Peng H; Zhang J; Zhang PP; Chen L; Tang LL; Yang XJ; He QM; Wen X; Sun Y; Liu N; Li YQ; Ma J
    J Exp Clin Cancer Res; 2019 Jan; 38(1):11. PubMed ID: 30621723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomal ERp44 derived from ER-stressed cells strengthens cisplatin resistance of nasopharyngeal carcinoma.
    Xia T; Tian H; Zhang K; Zhang S; Chen W; Shi S; You Y
    BMC Cancer; 2021 Sep; 21(1):1003. PubMed ID: 34493236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.